OptiBiotix Health PLC OptiBiotix obtains BRC accreditation
05 Janvier 2022 - 8:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
05 January 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
OptiBiotix obtains British Retail Consortium accreditation
One of the leading international food safety standards
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing unique science and human study-based compounds that
modulate the microbiome to address metabolic syndrome and diabetes,
systemic low-grade inflammation, obesity, cardiovascular disease,
high cholesterol and to support healthy aging has achieved British
Retail Consortium ('BRC') accreditation.
BRC was the first standard to meet the Global Food Safety
Initiative ('GFSI') benchmark, which means it is accepted by many
of the world's biggest retailers, such as Tesco and Walmart. The
certification ensures customers have confidence in OptiBiotix's
products and it allows the Company to do business with those
retailers, manufacturers, ingredients companies and food service
organisations who specify certification as part of their approval
process (most large retailers and their suppliers). It incorporates
food safety management systems and internationally accepted best
practice to ensure the safety and quality of products and in doing
so reduces the risk of recalls.
René Kamminga, C EO of O pti B i oti x Limited, c o mmented :
"We are very pleased to announce our BRC accreditation which
supports our commercial strategy of selling final product solutions
to partners in the retail channel containing our science backed pro
and prebiotic ingredients. I am particularly proud of our team
which achieved this accreditation in a relatively short period of
time."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASSUFWLEESEFF
(END) Dow Jones Newswires
January 05, 2022 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Optibiotix Health (LSE:OPTI)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024